📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial (2022)

First Author: Gombe B

Attributed to: A combination efficacy study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEP) – supplementary funding for MPLA-Liposomes funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0275927

PubMed Identifier: 36327320

Publication URI: http://europepmc.org/abstract/MED/36327320

Type: Journal Article/Review

Parent Publication: PLOS ONE

Issue: 11

ISSN: 1932-6203